G
Giuseppe Paolisso
Researcher at Seconda Università degli Studi di Napoli
Publications - 518
Citations - 36557
Giuseppe Paolisso is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Insulin & Diabetes mellitus. The author has an hindex of 85, co-authored 479 publications receiving 33028 citations. Previous affiliations of Giuseppe Paolisso include National Institutes of Health & University of Udine.
Papers
More filters
Journal ArticleDOI
The link between insulin resistance and mobility limitation in older persons.
TL;DR: Interventions aimed at correcting insulin resistance may have a potential role in preventing or at least slowing down functional decline in the elderly population, promoting a better quality of life and potentially extending the "healthspan".
Journal ArticleDOI
Effect of human calcitonin (hCT) on glucose- and arginine-stimulated insulin secretion
Saverio Sgambato,Nicola Passariello,Giuseppe Paolisso,Armando Marano,Raffaello Buoninconti,Tesauro P +5 more
TL;DR: The results clearly demonstrate that physiologic doses of hCT are able to inhibit arginine induced insulin secretion in normal man, controlling post-prandial hypercalcemia by its osteotrophic effect and by its action upon calcium redistributed within the cells.
Journal ArticleDOI
Effect of sparteine sulfate on insulin secretion in normal men.
TL;DR: It is demonstrated that in normal man sparteine sulfate, administrated by intravenous infusion, is able to increase either basal or glucose-induced insulin secretion.
Journal ArticleDOI
Glycemic control and acute coronary syndrome: the debate continues
TL;DR: DM patients are considered, as a population of patients with different clinical characteristics, that render more difficult the best clinical pharmacological and non-pharmacological treatment (pPCI) to reduce worse prognosis during AMI, and have to improve current clinical diagnosis and treatment.
Journal ArticleDOI
Adverse drug events in older geriatric patients: does safe prescribing exist?
TL;DR: There is consistent and increasing literature that older patients are at a higher risk of adverse drug events (ADEs) in the presence of frailty, comorbidities, polypharmacy and geriatric conditions, which all in turn lead to negative clinical outcomes, including hospitalization and death.